CalciMedica Inc. (NASDAQ:CALC) Short Interest Down 47.6% in July

CalciMedica Inc. (NASDAQ:CALC) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 503,070 shares, a decline of 47.6% from the July 15th total of 960,731 shares. Currently, 4.4% of the shares of the company are short sold. Based on an average daily volume of 277,430 shares, the days-to-cover ratio is currently 1.8 days.

Analysts Set New Price Targets

Several equities analysts recently issued reports on CALC shares. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Finally, Weiss Ratings lowered CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

CalciMedica Stock Performance

Shares of CALC stock traded down $0.01 during mid-day trading on Tuesday, hitting $0.65. The stock had a trading volume of 61,439 shares, compared to its average volume of 1,047,244. CalciMedica has a fifty-two week low of $0.46 and a fifty-two week high of $7.20. The firm has a market cap of $10.24 million, a PE ratio of -0.48 and a beta of 0.91. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. The company’s 50-day simple moving average is $0.80 and its 200-day simple moving average is $0.72.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.17). Sell-side analysts anticipate that CalciMedica will post -1.05 earnings per share for the current year.

Insider Buying and Selling

In other CalciMedica news, Director Fred A. Middleton bought 248,972 shares of CalciMedica stock in a transaction dated Thursday, June 25th. The stock was acquired at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the acquisition, the director owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. This represents a 30.57% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 28.25% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

Large investors have recently modified their holdings of the business. 180 Wealth Advisors LLC lifted its holdings in shares of CalciMedica by 297.2% in the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after buying an additional 94,650 shares during the period. Boothbay Fund Management LLC acquired a new position in CalciMedica during the fourth quarter worth $506,000. PVG Asset Management Corp purchased a new position in CalciMedica in the fourth quarter worth $302,000. Renaissance Technologies LLC raised its position in CalciMedica by 45.0% in the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after acquiring an additional 39,775 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after acquiring an additional 34,386 shares during the period.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.